KPV Peptide: What the Research Shows

At a glance

What it isA tripeptide of three amino acids (lysine, proline, valine). It is a small piece of a natural hormone called alpha-MSH.

Studied forIntestinal inflammation, in cell cultures and in mice.

Human evidenceNone found. FDA also found no human studies.

FDA statusNot an approved drug. Not on FDA’s list of bulk substances that pharmacies may compound. A federal decision was still pending when this page was reviewed.

SportNot named on the World Anti-Doping Agency’s 2026 Prohibited List. Athletes should check with their own anti-doping agency.

Last reviewed October 12, 2026. Regulatory status for these substances has been changing, so we re-check this page and update the date.

What the research shows

KPV is the last three amino acids of alpha-MSH, a hormone the body makes. A 2008 review explained why researchers were interested: KPV appeared to keep alpha-MSH’s anti-inflammatory effect without its effect on skin pigment. The evidence reviewed was from cells and animals. ^[1]

In a 2008 study in Gastroenterology, KPV given by mouth reduced the incidence of colitis in two mouse models, and reduced inflammation in human cell lines. ^[2] A second 2008 mouse study found a similar anti-inflammatory effect. ^[3] A 2017 mouse study tested KPV carried in nanoparticles. ^[4]

We found no study of KPV in people. FDA reached the same conclusion: the agency identified no human exposure data on drug products containing KPV by any route. ^[5]

What is still unknown

Whether KPV has any effect in people, at any dose.
Whether it is safe in people. There is no published human safety data.
Whether an oral liposomal supplement delivers KPV to the gut or anywhere else. Mouse colitis studies used specific doses and routes that may not apply.

Where it stands with FDA and in sport

FDA has not approved any drug that contains KPV. FDA’s review states that it “has not identified any human exposure data on drug products containing KPV administered via any route of administration.” ^[6]

KPV was among the substances considered at FDA’s July 2026 advisory committee on compounding. FDA staff proposed that it not be added to the compounding list. Media reports say the committee voted in favor. The vote is advisory, and we found no final FDA action when this page was reviewed. ^[7]

The product

Quicksilver Scientific Oral Liposomal BPC + KPV

Quicksilver Scientific sells a combination oral liposomal liquid, 1 mL per serving, 30 mL bottle. Its Supplement Facts panel lists “BPC (as Pentadeca Short Chain Amino Acids)” at 1,000 mcg and KPV at 1,000 mcg per serving. The label directs refrigeration after delivery.^[8]

It is sold as a dietary supplement, not an FDA-approved drug. We are not aware of published human studies of KPV, of BPC-157 taken by mouth, or of this combination.

Quicksilver does not sell KPV on its own.

If you are curious about this product, talk with a KOI clinician first. We review your history, your medications and your labs, and we will tell you plainly what is known and not known.

Sources

Good to know

Is there any human research on KPV?

We found none, and FDA found none. The research so far is in cell cultures and mice.

Is KPV the same as BPC-157?

No. They are different peptides. Quicksilver Scientific sells a product that contains both.

Go deeper

Explore the Ēnel Health Peptide Atlas

Ēnel Health publishes a free library of peptides, with each compound graded on the human evidence that exists and every entry cited to its sources.

Explore the Peptide Atlas

Not sure what makes sense for you?

Start with a free 15-minute consult. A KOI clinician will review your history, your medications and your labs before anything else.

Book a Free Consult

This page is for education. It is not medical advice and does not replace care from a licensed clinician.

Locations

Language

KPV